Ankylosing Spondylitis Market Growth & Trends
The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.
Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.
Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province’s public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.
Ankylosing Spondylitis Market Report Highlights
- The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.
- The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.
- The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023
- Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
- For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Ankylosing Spondylitis Market Variables, Trends, & Scope
Chapter 4. Global Ankylosing Spondylitis Market: Drug Class Estimates & Trend Analysis
Chapter 5. Global Ankylosing Spondylitis Market: Distribution Channel Estimates & Trend Analysis
Chapter 6. Global Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
Companies Mentioned
- AbbiVie, Inc.
- Amgen, Inc.
- Pfizer, Inc.
- Johnson & Johnson, Inc.
- Novartis AG
- UCB, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Zydus Lifescience ltd.
- Izana Bioscience
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 5.78 Billion |
| Forecasted Market Value ( USD | $ 9.12 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
